INECO Neurociencias Oroño
Rosario, Argentina
9 recruiting
Showing 1–20 of 25 trials
Recruiting
Phase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Type 2 Diabetes
Eli Lilly and Company55 enrolled51 locationsNCT06739122
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled244 locationsNCT06935357
Recruiting
Phase 3
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Generalized Myasthenia Gravis
Vor Biopharma180 enrolled111 locationsNCT06456580
Recruiting
Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Chronic Migraine in Children
H. Lundbeck A/S285 enrolled84 locationsNCT04965675
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx218 enrolled75 locationsNCT06920004
Recruiting
Phase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Migraine
H. Lundbeck A/S600 enrolled70 locationsNCT05164172
Recruiting
Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Episodic Migraine
H. Lundbeck A/S315 enrolled65 locationsNCT05897320
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP
argenx160 enrolled61 locationsNCT07091630
Recruiting
Phase 2
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
Asthma Acute
Connect Biopharm LLC160 enrolled59 locationsNCT06940141
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled635 locationsNCT06935370
Recruiting
Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled253 locationsNCT07415044
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled129 locationsNCT07369011
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
OsteoarthritisOverweight or Obesity
Eli Lilly and Company900 enrolled160 locationsNCT07353931
Recruiting
Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Peripheral Arterial Disease
Eli Lilly and Company1,205 enrolled138 locationsNCT07223593
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled169 locationsNCT07321886
Recruiting
Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled752 locationsNCT07157774
Recruiting
Phase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Bipolar Disorder
Eli Lilly and Company400 enrolled87 locationsNCT07286175
Recruiting
Phase 3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled138 locationsNCT06463587